OncoMatch/Clinical Trials/NCT07285694
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Is NCT07285694 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AB-3028 for metastatic castration resistant prostate cancer (mcrpc).
Treatment: AB-3028 — This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 overexpression (PSMA+ by PSMA PET)
PSMA+ by PSMA PET
Disease stage
Metastatic disease required
Prior therapy
Must have received: androgen receptor pathway inhibitor — prostate cancer
Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy
Cannot have received: systemic therapy for CRPC
Exception: within 14 days prior to scheduled protocol required leukapheresis
Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- University of Iowa and Holden Comprehensive Cancer Center · Iowa City, Iowa
- Perlmutter Cancer Center - NYU Langone Health · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify